RANK Ligand Helps Immunity to Leishmania major by Skewing M2-Like Into M1 Macrophages

Area of Science:

• Immunology
• Cell Biology
• Parasitology

Background:

• Macrophages are key hosts for Leishmania major, causing cutaneous leishmaniasis.
• Immunity relies on CD4 T-cell cytokines and macrophage activation (M1 vs. M2 phenotypes).
• IFN-γ induces M1 macrophages for parasite killing, while IL-4 promotes M2 macrophages that shelter the parasite.

Purpose of the Study:

• To investigate how RANKL directly modulates macrophage phenotypes and immunity to Leishmania major.
• To explore the role of RANKL in the crosstalk between T cells and macrophages in restricting parasite infection.

Main Methods:

• Treatment of inflammatory peritoneal macrophages from B6 mice with RANKL and/or IFN-γ.
• Analysis of macrophage differentiation markers (F40/80, CD301, CD206).
• Measurement of cytokine production (IL-12, TNF-α) and enzyme expression (arginase-1, iNOS).
• Assessment of nitric oxide (NO) and reactive oxygen species (ROS) production.
• Evaluation of macrophage-mediated parasite killing in vitro.

Main Results:

• RANKL and IFN-γ induced differentiation into mature F40/80hi macrophages producing IL-12 and TNF-α.
• RANKL and IFN-γ downregulated M2 markers (MGL, arginase-1, CCL17) and synergistically enhanced iNOS expression and NO production.
• Combined RANKL and IFN-γ treatment promoted NO- and ROS-dependent killing of Leishmania major by macrophages.

Conclusions:

• RANKL cooperates with IFN-γ to induce a M2-like to M1 macrophage phenotype shift.
• This RANKL-IFN-γ synergy enhances macrophage-mediated immunity against Leishmania major.
• RANKL, in combination with IFN-γ, represents a potential therapeutic strategy for leishmaniasis by promoting M1 macrophage effector functions.